Velicept is a company headquartered in the United Kingdom.
Velicept was developing solabegron, a selective beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). The company ceased operations in 2020.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.